Product is good
Data accumulated from animal experiments conducted in acute ischemic stroke models with and without diabetes have also demonstrated a dose-dependent reduction of infarct volume in the brain by GLP-1RAs, when administered before or during the acute phase of ischemia at reperfusion or with some delay after the onset of reperfusion [60,61,62, 70]
In individuals with advanced -cell dysfunction, supplementing insulin therapy with pramlintide, the first and currently only approved injectable short-acting selective analog of amylin, has demonstrated efficacy in enhancing both postprandial and overall glycemic control in both type 2 diabetes (T2D) and type 1 diabetes (T1D) without increasing the risk of hypoglycemia or weight gain
A few, including Wegovy, Zepbound, and Saxenda (liraglutide), are FDA-approved for weight loss
Two ways GLP-1 + GIP medication helps you lose weight It works on your appetite and your metabolism
This rebound is likely driven by increased food intake following drug discontinuation